WallStSmart

Medtronic PLC (MDT)vsQuanterix Corp (QTRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 25447% more annual revenue ($35.48B vs $138.90M). MDT leads profitability with a 13.0% profit margin vs -77.1%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

QTRX

Hold

42

out of 100

Grade: D

Growth: 6.0Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 2/9Altman Z: 1.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for QTRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

QTRX3 strengths · Avg: 9.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
24.7%8/10

Revenue surging 24.7% year-over-year

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

QTRX4 concerns · Avg: 3.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Market CapQuality
$179.31M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : QTRX

The strongest argument for QTRX centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : QTRX

The primary concerns for QTRX are EPS Growth, Altman Z-Score, Market Cap.

Key Dynamics to Monitor

MDT profiles as a value stock while QTRX is a growth play — different risk/reward profiles.

QTRX carries more volatility with a beta of 1.12 — expect wider price swings.

QTRX is growing revenue faster at 24.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Quanterix Corp

HEALTHCARE · MEDICAL DEVICES · USA

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?